Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on June 27, 2006
Japanese Journal of Clinical Oncology 2006 36(8):523-526; doi:10.1093/jjco/hyl057
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/8/523    most recent
hyl057v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chou, W.-C.
Right arrow Articles by Chang, J. W.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chou, W.-C.
Right arrow Articles by Chang, J. W.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Case Report

Different Responses to Gefitinib in Lung Adenocarcinoma Coexpressing Mutant- and Wild-Type Epidermal Growth Factor Receptor Genes

Wen-Chi Chou1, Shiu-Feng Huang2, Kun-Yang Yeh3, Hung-Ming Wang1, Mei-Ying Liu1, Jia-Juan Hsieh1, Yun-Chung Cheung4 and John Wen-Cheng Chang1

1 Departments of Hematology-Oncology, 4 First Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, 2 Division of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli and 3 Department of Hematology-Oncology, Pahai Hospital, Yilan, Taiwan, ROC

For all reprints and all correspondence: John Wen-Cheng Chang, 155 Tung Hwa North Road, Taipei 105, Taiwan, ROC. E-mail: wen1902{at}hotmail.com

Received March 20, 2006; accepted April 17, 2006

Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.

Key Words: lung cancer (diagnosis & staging, translational oncology • gene profiling, translational oncology • signal transduction, EGFR mutation)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.